Abstract | PURPOSE: To evaluate ocular hypertension (OHT) after Ozurdex injection to determine the incidence of OHT, therapy for OHT, and any associative factors such as diagnosis, underlying glaucoma and therapy, or sequential Ozurdex injection(s). METHODS: Retrospective consecutive case series with patients receiving one or more intravitreal Ozurdex implantations at a tertiary care academic center. Ocular hypertension was defined as a single measurement of ≥30 mmHg or an increase of ≥10 mmHg from baseline. RESULTS: CONCLUSION: Patients (26.9%) who received Ozurdex developed OHT. Glaucoma or glaucoma-suspicion factors were present in all patients who required invasive surgery for glaucoma. A greater proportion of patients who received multiple injections had an intraocular pressure elevation, but the relative intraocular pressure increase was not significant.
|
Authors | Eric K Chin, David R P Almeida, Gabriel Velez, Kunyong Xu, Maria Peraire, Maria Corbella, Yasser M Elshatory, Young H Kwon, Karen M Gehrs, H Culver Boldt, Elliott H Sohn, Stephen R Russell, James C Folk, Vinit B Mahajan |
Journal | Retina (Philadelphia, Pa.)
(Retina)
Vol. 37
Issue 7
Pg. 1345-1351
(Jul 2017)
ISSN: 1539-2864 [Electronic] United States |
PMID | 27806001
(Publication Type: Journal Article)
|
Chemical References |
- Delayed-Action Preparations
- Dexamethasone
|
Topics |
- Delayed-Action Preparations
- Dexamethasone
(administration & dosage, adverse effects)
- Female
- Follow-Up Studies
- Humans
- Intraocular Pressure
(drug effects)
- Intravitreal Injections
- Macular Edema
(drug therapy)
- Male
- Middle Aged
- Ocular Hypertension
(chemically induced, physiopathology)
- Prognosis
- Retrospective Studies
- Time Factors
|